DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "World Liver Diseases Therapeutics Market - Opportunities and Forecasts, 2014 - 2022" report to their offering.
Liver diseases are one of the most prevalent diseases in the world. The commercialization of a variety of liver therapeutics drugs has made the treatment of these diseases possible. The report provides an in-depth intelligence about current market trends of the liver diseases therapeutics market. The objective of this report is to study the demand for these therapeutics in the market and to assess its growth.
The increase in the aging population has increased the incidences of chronic liver diseases, which are heavily driving the liver diseases therapeutics market. Also, the increasing consumption of alcohol would lead to higher demand for these therapeutics. The associated side effects from some of these therapeutics, and government regulations, act as restraining forces for this market. The increasing awareness regarding heath issues and technological advancements would pave the way for growth of this market in the future.
On the basis of disease type, this market is classified into virus-induced liver disease/hepatitis, liver tumors/liver cancer, congenital liver defects, autoimmune liver disorders, alcohol-induced liver disease, chronic liver disease and non-alcoholic fatty liver. Among all these diseases, alcohol-induced liver diseases and hepatitis are most common.
On the basis of therapeutics, this market is classified into Alcohol-Induced Liver Disease, Autoimmune Liver Disorder, Hepatocellular Carcinoma, Non-Alcoholic Fatty Liver Disease, Viral/Hepatitis Liver Disorder, Hepatitis B, Hepatitis C, Hepatitis D and Hepatitis E. The most common types of therapeutics include alcohol-induced liver diseases and hepatitis.
Companies operating in the liver disease therapeutics market are adopting product launch and approval as key developmental strategies.
Key companies included in the report are Abbott Laboratories, Astellas Pharma, Inc., Gilead Science, Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche.
For more information about this report visit http://www.researchandmarkets.com/research/8l3dcd/world_liver.